1. Optimization of 8-Hydroxyquinolines as Inhibitors of Catechol O-Methyltransferase
- Author
-
Martyn D. Wood, Anna Kolobova, Florence Moureau, Glen Ernst, Daniel Akuma, Ingrid P. Buchler, Florian Montel, James C. Barrow, Huijun Wei, Dominique Swinnen, Gregory V. Carr, Michael S. Poslusney, Emilie Jigorel, Vinh Au, Pablo De León, Michael DePasquale, Martha Kimos, Monika Sarah E.D. Schulze, and Yifang Huang
- Subjects
Male ,Models, Molecular ,0301 basic medicine ,Protein Conformation ,Stereochemistry ,Catechol O-Methyltransferase ,Article ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Dopamine ,Drug Discovery ,medicine ,Animals ,Tissue Distribution ,Chelation ,chemistry.chemical_classification ,Catechol ,Catechol-O-methyl transferase ,biology ,Quinoline ,Brain ,Catechol O-Methyltransferase Inhibitors ,Active site ,Oxyquinoline ,Rats ,030104 developmental biology ,Enzyme ,chemistry ,Drug Design ,biology.protein ,Molecular Medicine ,Hydroxyquinolines ,030217 neurology & neurosurgery ,medicine.drug - Abstract
A series of 8-hydroxy quinolines were identified as potent inhibitors of catechol O-methyltransferase (COMT) with selectivity for the membrane-bound form of the enzyme. Small substituents at the 7-position of the quinoline were found to increase metabolic stability without sacrificing potency. Compounds with good pharmacokinetics and brain penetration were identified and demonstrated in vivo modulation of dopamine metabolites in the brain. An X-ray co-crystal structure of compound 21 in the S-COMT active site shows chelation of the active site magnesium similar to catechol-based inhibitors. These compounds should prove useful for treatment of many neurological and psychiatric conditions associated with compromised cortical dopamine signaling.
- Published
- 2018